+1 877 705 191424 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years - 85Years
All Genders
ID06261801

Efficacy of Electroacupuncture Combined With Pregabalin in Treating Trigeminal Herpetic Neuralgia A Multicenter Randomized Controlled Trial

Led by The Third People's Hospital of Hangzhou · Updated on 2025-02-21

102

Participants Needed

1

Research Sites

21 weeks

Total Duration

On this page

Sponsors

T

The Third People's Hospital of Hangzhou

Lead Sponsor

T

The Third Affiliated hospital of Zhejiang Chinese Medical University

Collaborating Sponsor

AI-Summary

What this Trial Is About

Trigeminal herpetic neuralgia, a common form of Zoster-associated Pain ZAP, affects people of all ages and poses a significant burden worldwide. Researchers are conducting a randomized controlled trial to evaluate electroacupuncture EA as a treatment for ZAP, focusing on its effectiveness and safety compared to pregabalin. The study aims to determine if EA can be a substitute for pregabalin in managing this condition. Participants are randomly assigned to one of three groups a medication group taking 150 mg pregabalin capsules twice daily for 4 weeks an EA group receiving electroacupuncture treatments three times per week for 4 weeks total of 12 sessions, targeting specific acupoints on the affected side with electrical stimulation and a combined EA plus medication group receiving both treatments concurrently. Each group undergoes a 3-month follow-up period after the interventions. During the study, participants will be assessed using the Visual Analog Score at baseline, during treatment, and in follow-up visits up to 16 weeks. Additional evaluations include pain questionnaires, sleep quality scales, depression and anxiety ratings, and health surveys. Researchers will monitor safety and treatment adherence throughout the study, which lasts several months from enrollment to final follow-up assessments.

CONDITIONS

Brief Title

Efficacy of Electroacupuncture Combined With Pregabalin in the Treatment of Trigeminal Herpetic Neuralgia: a Multicenter Randomized Controlled Trial Study Protocol

Who Can Participate

Age: 18Years - 85Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Meet diagnostic criteria for trigeminal Zoster-associated Pain with disease duration of 1 to 3 months
  • Have a Visual Analog Scale (VAS) pain score between 4 and 7
  • Be between 18 and 85 years old, any gender
  • Have clear consciousness and ability to communicate
  • Voluntarily participate and sign informed consent
Not Eligible

You will not qualify if you...

  • Do not meet inclusion criteria
  • Have herpes zoster on trunk or limbs, or special types like meningeal or visceral herpes zoster
  • Are pregnant or breastfeeding
  • Are allergic to pregabalin or acupuncture
  • Have severe organ damage, cognitive problems, mental disorders, aphasia, or other serious diseases
  • Have severe skin diseases
  • Have a pacemaker
  • Have participated in other clinical studies within the past 3 months

Research Team

P

Pin Lin

C

Chengcheng Kong

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here